In phase I (pre-cohort), patients received 384 nephrotoxic alerts (55%) with 78 (20%) of them provoking a change or discontinuation of the nephrotoxic drug. In phase II (post-cohort) this value increased to 154 out of 526 (29%) after implementation of the CDSS (p<0.01).